Aravive (STU:VE11) Accounts Payable & Accrued Expense

: €7.17 Mil (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

Aravive's quarterly accounts payable & accrued expense declined from Mar. 2023 (€13.49 Mil) to Jun. 2023 (€8.72 Mil) and declined from Jun. 2023 (€8.72 Mil) to Sep. 2023 (€7.17 Mil).

Aravive's annual accounts payable & accrued expense increased from Dec. 2020 (€3.97 Mil) to Dec. 2021 (€9.80 Mil) and increased from Dec. 2021 (€9.80 Mil) to Dec. 2022 (€14.64 Mil).

Aravive Accounts Payable & Accrued Expense Historical Data

The historical data trend for Aravive's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable & Accrued Expense

1.57

2.32

3.97

9.80

14.64

Aravive Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Accounts Payable & Accrued Expense																16.24	14.64	13.49	8.72	7.17

Aravive Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Aravive (STU:VE11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

ARAV:USA VE11:Germany

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (STU:VE11) Headlines

No Headlines